Atherosclerotic Coronary Vulnerable Plaque: Correlation With Coronary Artery Calcium

Coronary Artery Disease Clinical Trial

Official title:

Atherosclerotic Coronary Vulnerable Plaque: Correlation With Coronary Artery Calcium

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01830062
• Other study ID #: CACS NIRS
• Status: Withdrawn
• Phase: N/A
• Start date: November 2013
• Est. completion date: June 2021

Study information

• Verified date: June 2021
• Source: Medstar Health Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to compare the relationship between the coronary artery calcification assessed by MDCT with the plaque characteristics and necrotic lipid core content of non-intervened coronary segments assessed with near infrared spectroscopy (NIRS) in patients with symptomatic coronary artery disease (CAD).

Description:

A total of 60 patients, from a single center, who meet all of the study inclusion criteria and none of the study exclusion criteria will be prospectively enrolled in this study. Qualifying patients will be referred to the study site for clinically indicated, non-emergent cardiac catheterization with NIRS evaluation, either proceeded or followed by coronary artery calcium score (CACS) evaluation.

Qualifying patients that are referred directly to cardiac catheterization with NIRS assessment secondary to symptoms or abnormal functional test will be sent for cardiac CACS assessment following the catheterization before discharge from the hospital. In this group, patients who require ad hoc PCI upon initial angiography will be excluded to avoid artifacts on CACS. In patients who are referred for a clinically indicated cardiac catheterization with IVUS evaluation within 3 months after MDCT with CACS, NIRS of at least two (2) major epicardial vessels will be completed prior to any (if necessary) coronary revascularization.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 2021
• Est. primary completion date: January 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient is =18 years of age

• Patient is clinically indicated due to angina, abnormal functional test or other ischemic symptoms to undergo non-emergent cardiac catheterization with IVUS evaluation i.If the patient has not had a cardiac MDCT with CACS meeting the protocol requirements within 3 months prior to the cardiac catheterization, the patient is able to undergo CACS following LipiScan IVUS and NIRS evaluation, prior to any coronary revascularization ii. If the patient has had a cardiac MDCT evaluation with CACS meeting the protocol requirements within 3 months prior to the cardiac catheterization, LipiScan IVUS and NIRS imaging will be completed in at least two (2) major epicardial vessels prior to any coronary revascularization

• At least two (2) major epicardial native vessels are suitable for interrogation by LipiScan IVUS imaging and NIRS evaluation, defined as:

i.At least 30 mm of vessel that is > 2.0mm in diameter ii.No other contraindications to imaging

• No contraindications for LipiScan IVUS and NIRS evaluation

• No contraindications for CACS evaluation by MDCT

• Subject must be able to provide informed consent form and comply with the protocol requirements

Exclusion Criteria:

• Evidence of clinical hemodynamic instability in the 6 hours before either procedure

• Prior history of percutaneous coronary intervention (PCI) with stent placement

• Prior history of bypass grafts

• Female subject that is pregnant or lactating

• Any other factor that the investigator feels would put the patient at increased risk or otherwise make the patient unsuitable for participation in the protocol

Related Conditions & MeSH terms

• Coronary Artery Disease

Intervention

Other:
• NIRS
Near infrared spectroscopy of at least 2 major epicardial vessels
• CACS
Coronary artery calcium score assessed by multi-slice computed tomography

Locations

Country	Name	City	State
United States	MedStar Washington Hospital Center	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Medstar Health Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation between CACS and LCBI	The primary endpoint for this study is individual patient level correlation between the total CACS of the entire coronary tree with the max LCBI4mm within the vessels imaged.	maximum duration of 3 months between CACS and NIRS
Secondary	Vessel level correlation of CACS and LCBI	Vessel level and individual coronary artery level (LM, LAD, LCx, RCA) analysis of CACS with max LCBI4mm and total LCBI for the vessel imaged	maximum of 3 months between CACS and NIRS
Secondary	Vessel level comparison of angiographic and IVUS parameters	Vessel level comparison of angiographic and IVUS parameters with yellow plaque defined by LCBI (both max LCBI4mm and total vessel LCBI)	maximum of 3 months between CACS and NIRS
Secondary	Segment level analysis of CACS, IVUS and lipid core plaque in patients with abnormal CT	In subset of patient where coronary angiography and NIRS is driven by patient with abnormal CT coronary angiogram, the CT angiographic parameters are utilized for Segment level analysis between the CACS, IVUS and lipid core plaque	maximum of 3 months between CACS and NIRS